Tumor-specific gene therapy can be achieved if a tumor-specific promoter can be identified. In this study the authors investigated the use of the rat insulin promoter (RIP) for insulinoma-specific expression of a reporter gene. Insulinoma-specific cytotoxicity using the suicide gene thymidine kinase (tk) was studied both in vitro and in vivo. RIPtk gene therapy, delivered by a nontoxic, noninflammatory liposomal delivery system, was used in an insulinoma ICR/SCID mouse model to prevent hypoglycemic death.
Insulinomas are the most common of the islet cell tumors. Ninety percent of beta cell tumors are benign, but the complication rate associated with their removal is significant: the fistula rate is 11%. 1 Malignant insulinomas have a 63% 5-year recurrence rate, with an average survival of less than 4 years. 1 Further, there is no effective medical treatment for the devastating symptoms associated with hyperinsulinemia of insulinoma.
With the identification of tissue-specific promoters, tumors can be targeted by gene therapy. The rat insulin promoter (RIP) is an example of a cell-specific promoter that is activated in cells that produce insulin. NIT-1 cells are a mouse beta cell tumor line derived from the nonobese diabetic mouse. 2 The purposes of this study were to use RIP to target NIT-1 cells for genetic manipulation and to determine the transcription factors responsible for NIT-1 cellspecific activation of RIP. An ICR/SCID mouse insulinoma model was used to determine whether gene therapy could be effective in vivo to prevent hypoglycemic death in this model.
METHODS

Generation of RIPlacZ and RIPtk Constructs
All restriction enzymes unless otherwise noted are from Gibco-BRL (Bethesda, MD). The plasmid pD46.21 (provided by Dr. Franco DeMayo, Department of Cell Biology, Baylor College of Medicine), which contains a ␤-galactosidase gene with a polyadenylation signal and a nuclear localization signal, was digested with HindIII, blunt-ended with Klenow, and digested with BamHI. RIP in Blue-Script KS ϩ (provided by Dr. Ming-Jer Tsai, Department of Cell Biology, Baylor College of Medicine) was isolated with SstII, blunt-ended with T4 polymerase (Promega, Madison, WI), digested with BamHI, and ligated into restriction endonuclease-treated pD46.21 in accord with the standard procedure. Digesting with NotI and identifying a 4.1-kb band verified the construct.
The RIP-thymidine kinase (tk) construction was generated in two steps. First, the coding sequence of tk, 66 bp upstream from the ATG, was isolated from pMC1TK-6 (provided by Dr. Arthur Beaudet, Department of Cell Biology, Baylor College of Medicine) with NotI, blunt-ended with Klenow, and digested with BamHI. The isolated tk gene was then ligated with growth hormone polyA (GhpA), in Blue-Script, which was digested with EcoRI, blunt-ended with Klenow, and digested with BamHI. This ligation was verified with HindIII.
Thymidine kinase-GHpA in Blue-Script was further digested with BamHI and NotI and ligated with isolated 0.502 kb of RIP previously digested with BamHI and NotI. Digesting with BamHI and NotI and identifying a 0.5-kb band verified the construct.
Transient Transfection of Genetic Constructs
All cell lines were obtained from the Tissue Core Facility at Baylor College of Medicine and grown in their respective media as recommended by ATCC (Bethesda, MD). Cells were plated into six-well dishes growing in logarithmic phase (60 -80% confluent) 24 hours before transfection. All cells were transfected with 1 g DNA per well (RIPlacZ, RSVlacZ, RIPtk, hollow vector, and MC1tk). The DNA was mixed with 6 L Fugene (Boehringer Mannheim, Indianapolis, IN) in 94 L Dulbecco's modified Eagle's medium without serum. One hundred microliters of solution was added to each well by mixing gently.
Detection of ␤-Galactosidase Gene Expression, X-gal Staining
NIT-1, CV-1 (monkey renal cell), F9 (mouse embryonic carcinoma cell), 3T3 (mouse fibroblast cell), and H411 (mouse lung cell) cells were transfected with either RIPlacZ or RSVlacZ (provided by Dr. Jeff Rosen, Department of Cell Biology, Baylor College of Medicine). RSVlacZ served as a positive control to ensure that all cells were sufficiently transfected. Thirty-six hours after transfection cells were stained with X-gal staining solution to detect the presence of the ␤-galactosidase protein. This was done by first washing the cells with cold phosphate-buffered saline (twice) and fixing them with 0.5% glutaraldehyde for 5 minutes. Cells were then washed with cold phosphate-buffered saline (twice), and an X-gal staining solution containing 1 mol/L MgCl 2 , 5 mol/L NaCl, 0.5 mol/L HEPES (pH 7.3), 30 mmol/L potassium ferricyanide, 30 mmol/L potassium ferrocyanide, and 2% X-gal solution was added. Cells were then incubated at 37°C for 24 hours to develop the color. An independent observer verified the presence of blue color. The experiment was repeated four times and a total of 16 wells were examined per cell type.
Detection of ␤-Galactosidase Gene Expression Using a Luminometer
NIT-1 and F9 cells transfected with either RIPlacZ or RSVlacZ were subjected to ␤-galactosidase Reporter Gene Assay (Tropix, Bedford, MA). The assay was carried out in triplicate. Protein levels were determined using Bradford's protein assay (Sigma, St. Louis, MO). Results are represented in light units and adjusted for protein content.
Ganciclovir Dose-Response Curve for NIT-1 Cells in Culture
NIT-1 cells were plated into a 96-well plate at a density of 5,000 cells per well and treated with ganciclovir (0.1-2.5 g/mL) to determine a dose-response curve to ganciclovir alone. The cells were treated daily for 5 days and cell viability was ascertained with an MTS assay (Promega, Madison, WI).
Treatment of Transfected Cells With Ganciclovir
NIT-1 and F9 cells were transfected with either the RIPtk gene or a hollow vector (v) (negative control). A group of untransfected cells (C) was used to control for the effect of ganciclovir alone on cell death. As a positive control, F9 cells were transfected with a tk construct driven by a ubiquitous promoter (MC1tk) to ensure that the F9 cells were being sufficiently transfected and susceptible to the cytotoxic effects of tk in the presence of ganciclovir. Twentyfour hours after transfection the cells were replated into 96-well plates at a density of 5,000 cells per well and subjected to ganciclovir treatment at a dose of 0.5 to 0.20 g/mL. The medium was refreshed daily. Cell viability was determined using an MTS assay read at an absorbency of 490 nm. Percentage of cell death was calculated as (A minus B)/A, multiplied by 100, where A is the absorbency at 490 nm of transfected cells not treated with ganciclovir and B is the absorbency at 490 nm of transfected cells treated with ganciclovir. The percentage cell survival was calculated by subtracting the percentage cell death from 100.
NIT-1 mRNA Isolation and Analysis of Transcription Factors PDX-1 and BETA2
NIT-1 total RNA was extracted using RNAzol (Tel-Test, INC., Friendswood, TX). Briefly, cells were allowed to grow to confluence in large vented flasks. Medium was removed and 5 mL RNAzol was added. The cells were removed with the aid of a cell scraper and placed on ice for 15 minutes. Five hundred microliters of chloroform was added and the cells were spun for 15 minutes at 10,000 rpm at 4°C. The aqueous phase was removed and mixed with an equal volume of isopropanol and placed at 4°C for 15 minutes and then spun for 15 minutes at 15,000 rpm at 4°C. The pellet was then washed with 70% ethanol and re-spun at 15,000 rpm and allowed to dry.
Reverse transcriptase-polymerase chain reaction (RT-PCR) was performed using the Superscript Preamplification System for First Strand cDNA Synthesis kit (Gibco-BRL). Primers specific for mouse PDX-1 mRNA (forward 281-300 bps TGAACAGTGAGGAGCAGTAC and reverse 870 -889 bps TTTTCCACTTCATGCGACGG) and primers specific for both human and mouse BETA2 (forward bps 944 -964, CGC-CGAGTTTGAAAAAAATT and reverse bps 1227-1207, TTTTTCCGACGGAAGACATT) (BETA2 primers were provided by Dr. Ming-Jer Tsai, Department of Cell Biology, Baylor College of Medicine) were used. Standard ␤-actin primers were used as controls. The PCR program for all three primers was as follows: 2 minutes at 94°C, then 30 cycles of 1 minute at 94°C, 1 minute at 55°C, and 1 minute at 72°C and 5 minutes at 72°C for finishing. Five microliters of the PCR reaction were run on gel electrophoresis. A 600-bp band identified a positive for PDX-1 and a 300-bp band identified a positive for BETA2.
Nuclear Extracts and Electrophoretic Mobility-Shift Assays
NIT-1 nuclear extracts were isolated as described elsewhere. 3 Protein levels were determined using Bradford's protein assay. A double-stranded oligodeoxynucleotide probe that contained both a BETA2 site and a PDX-1 site within RIP (bp 350 -381 on RIP TTGGCCATCTGCT-GATCCACCCTTAATGGGAC) was labeled with ␣ 32 P dGTP by filling overhanging 5Ј ends with Superscript. Binding reactions were performed with 2.5 g protein and 1 L hot probe per lane on a 5% acrylamide gel with either nuclear extract alone or 100ϫ cold wild-type probe to assess protein binding. Supershift analysis for BETA2 and PDX-1 binding activity was performed by the addition of 1 L anti- 
Development of In Vivo Mouse Beta Cell Adenoma Model
Twelve female ICR/ICR/SCID mice, age 6 to 10 weeks, received intraperitoneal injections of 5 ϫ 10 6 NIT-1 cells. The cells were placed in 200 L phosphate-buffered saline before inoculation and delivered slowly through a 27-gauge needle. Once the injection was complete, the needle was kept in the abdominal cavity for 15 seconds and slowly withdrawn in an attempt to prevent subcutaneous spillage of tumor. An additional 12 female ICR/SCID mice, age 6 to 10 weeks, received an equal volume of phosphate-buffered saline and were used as controls. As an estimate of the presence of tumor, blood glucose was measured using a glucometer every other day. At death, the mice underwent necropsies.
Treatment of Beta Cell Adenomas (Insulinomas) In Vivo
Twenty-seven female ICR/SCID mice, age 6 to 10 weeks, received intraperitoneal injections of 5 ϫ 10 6 NIT-1 cells, and nine female ICR/SCID mice, age 6 to 10 weeks, received intraperitoneal injections of phosphate-buffered saline. At day 31 the mice were randomized to receive the RIPtk gene, the RIPlacZ gene, or nothing. The RIPlacZ construct served both as a control and to localize gene expression. The genes were delivered by intraperitoneally means of extruded DOTAP:cholesterol liposomes (liposomes provided by Dr. Nancy Smyth-Templeton, Center for Gene Therapy and Department of Cell Biology, Baylor College of Medicine) and mixed as previously described. 4 Briefly, 10 to 15 L concentrated DNA (Ϸ10 mg/mL) was mixed with 135 to 140 L D 5 W to a final volume of 150 L. This DNA was mixed with an equal volume of extruded DOTAP: cholesterol in D 5 W and the OD 400 was read where an OD of 0.8 to 1.2 was considered acceptable for gene delivery. Two hundred microliters of this combination were injected intraperitoneally into each mouse.
Six mice were randomized to receive the RIPtk gene followed by 7 days of ganciclovir (40 mg/kg given intraperitoneally). Six mice were randomized to receive the RIPlacZ gene followed by 7 days of ganciclovir (40 mg/kg given intraperitoneally). Six mice were randomized to receive phosphate-buffered saline followed by 7 days of ganciclovir (40 mg/kg given intraperitoneally). Six mice that were inoculated with NIT-1 cells were randomized to receive 7 days of ganciclovir (40 mg/kg given intraperitoneally). Six mice that were inoculated with NIT-1 cells were randomized to receive 7 days of phosphate-buffered saline.
Three mice that were inoculated with NIT-1 cells and three mice that were inoculated with phosphate-buffered saline were randomized to receive the RIPlacZ gene and Vol. 233 • No. 5
Beta Cell-Specific Gene Therapy then were killed 36 hours later. In these mice, tissues were fixed in 5% glutaraldehyde for 1 hour, were stained with X-gal staining solution for 24 hours, and were sectioned and counterstained with nuclear fast red. Analysis of treatment and gene placement consisted of measurement of blood glucose values, inhibition of animal death, and presence of blue nuclei after X-gal staining.
Statistics
X-gal staining of cells used in the experiment (NIT-1, CV-1, F9, 3T3, and H411) was compared using a chi-square test. The light units were adjusted for protein content and compared using an unpaired Student t test. Cell survival between different constructs and cell lines was compared with analysis of variance. Mouse blood glucose levels were compared with analysis of variance, and animal survival was compared by covariance matrix for the Wilcoxon statistics using chi-square. P Ͻ .05 represented significance.
RESULTS
Detection of ␤-Galactosidase Gene Expression, X-gal Staining
Only the beta cell line NIT-1 showed a blue color after transfection with RIPlacZ (n ϭ 16, P Ͻ .05). All cell lines transfected with RSVlacZ developed a blue color after X-gal staining, ensuring that all cell types were adequately transfected. The percentage of NIT-1 cells staining blue with the RSVlacZ construct equaled the percentage of bluestaining cells with the RIPlacZ construct and was assumed to be the transfection efficiency for NIT-1 cells for this experiment.
Detection of ␤-Galactosidase Gene Expression Using a Luminometer
Transfection of RIPlacZ resulted in a significant increase in ␤-galactosidase protein levels in NIT-1 cells versus F9 cells: 2.9 ϫ 10 5 light units for NIT-1 cells and 1.2 ϫ 10 5 light units for F9 cells (n ϭ 6, P Ͻ .05). Both cell types showed an equal amount of ␤-galactosidase after transfection with RSVlacZ: 3.7 ϫ 10 5 light units for NIT-1 cells and 3.5 ϫ 10 5 light units for F9 cells (n ϭ 6, P ϭ NS). This ensured that F9 cells were adequately transfected. Background light units were equal between cell types as well: 1.3 ϫ 10 5 light units for NIT-1 cells and 1.4 ϫ 10 5 light units for F9 cells (n ϭ 6, P ϭ NS).
Ganciclovir Dose-Response Curve for NIT-1 Cells in Culture
At ganciclovir doses greater than 0.25 g/mL, the percentage survival for untransfected NIT-1 cells significantly decreased (n ϭ 8, P Ͻ .05), suggesting that 0.20 g/mL was the maximum dose of ganciclovir that can be used to treat NIT-1 cells in culture.
Treatment of Transfected Cells With Ganciclovir
In cells transfected with RIPtk only, NIT-1 cells showed a significant and ganciclovir dose-dependent decrease in cell survival: 17.7% for 0.15 g/mL and 26.8% for 0.2 g/mL ganciclovir (Fig. 1 ). F9 cells showed no significant decrease in cell survival with the RIPtk gene after ganciclovir treatment. F9 cells transfected with the positive control MC1tk showed a significant decrease in cell survival: 15.5% for 0.15 g/mL and 24.3% for 0.2 g/mL ganciclovir. Neither cell type showed a significant decrease in sur- vival after transfection with a hollow vector (v) or with ganciclovir treatment alone (C).
NIT-1 RNA Isolation and RT-PCR Analysis of Transcription Factors PDX-1 and BETA2
NIT-1 cells showed a message for PDX-1 and BETA2 (Fig. 2) .
Nuclear Extracts and EMSA
Nuclear extract from NIT-1 cells showed binding to the labeled oligonucleotide in RIP that contained both the BETA2 and PDX-1 sites. Further, a supershift was observed with both the BETA2 and PDX-1 antibodies (see Fig. 2 ).
Creation of an In Vivo Mouse Beta Cell Adenoma Model
ICR/ICR/SCID mice injected intraperitoneally with 5 ϫ 10 6 NIT-1 cells showed no difference in blood sugar versus control mice until 8 days before their death. At this point the mice showed a rapid decline of blood glucose levels and died of presumed hypoglycemia (Fig. 3 ).
Targeting of Beta Cell Adenomas (Insulinomas) In Vivo
Mice injected with NIT-1 cells and RIPlacZ and stained for X-gal staining showed localization of NIT-1 cells in the small bowel mesentery. Brain, lung, liver, small bowel, and kidneys were examined, and these tissues did not stain blue.
Treatment of Beta Cell Adenomas (Insulinomas) In Vivo
Five of six experimental mice (receiving NIT-1 tumors, RIPtk gene, and ganciclovir) lived throughout the length of the experiment with no significant change in blood glucose values and were still alive 8 months after tumor injection. All of the other mice that received NIT-1 cells underwent a rapid decline in blood glucose values and died (Fig. 4) .
DISCUSSION
There is no effective medical treatment for the devastating symptoms associated with hyperinsulinemia. Insulinomas are the most common of the islet cell tumors. Ninety percent of these tumors are benign, but the complications associated with their removal are significant. Management of this disease has not changed significantly since Mayo first surgically explored it 4 years after the discovery of insulin by Banting and Best.
With the identification of tissue-specific promoters, tumors can be targeted by gene therapy. RIP is an example of a cell-specific promoter that is activated in cells that produce insulin. NIT-1 cells are a mouse beta cell tumor line derived from the nonobese diabetic mouse. 2 The purposes of this study were to use RIP to target NIT-1 cells for genetic manipulation and to determine the transcription factors responsible for NIT-1 cell-specific ICR/SCID activation of RIP.
An ICR/SCID mouse insulinoma model was used to determine whether promoter-specific gene therapy could be effective in vivo and prevent hypoglycemic death in this model. Cancer-specific promoters are being identified and used in an effort to modify the expression of tk in tumor cells. [5] [6] [7] [8] [9] [10] However, these therapies have limitations as a result of either the weakness of the promoter or the tissue specificity of its activation. 11 Since 1991, the herpes simplex tk gene, under the transcriptional control of a ubiquitous promoter, has been introduced into a host and caused significant cell death in the presence of ganciclovir. [12] [13] [14] [15] [16] [17] Ganciclovir, an analog of guanosine, requires both mammalian and viral tk to become active. In viral tk-containing cells, ganciclovir is double-phosphorylated into an intermediate that inhibits DNA synthesis by acting as a chain terminator, killing dividing cells. 18, 19 However, tk with a ubiquitous promoter is not cell-specific, limiting its use as a cytotoxic agent.
The rat insulin promoter is a relatively strong promoter and is beta cell-specific. It has been determined that 0.502 kb RIP contains the essential elements to maximally drive the expression of a gene. 20 Identification of the essential parts of the promoter has allowed the development of smaller constructs, making creating constructs technically easier, increasing transfection efficiency in vitro, and aiding in the development of in vivo gene delivery systems.
Extruded DOTAP: cholesterol or liposome gene delivery is superior to viral vector gene therapy. They are easy to use and inexpensive. Although only a transient delivery system, liposomes have an additional benefit over viral vectors: they are neither toxic nor immunogenic and can be given more than once.
NIT-1 cells are a mouse beta cell adenoma cell line derived from the nonobese diabetic mouse. 2 The cells form beta cell tumors when injected into the peritoneum of mice, with the mice dying of hypoglycemia within 100 days. Mouse embryonic carcinoma cell line F9, mouse fibroblast cell line 3T3, and mouse lung cell line H411 were chosen because they represent a variety of rodent cell types. Monkey renal CV-1 cells were chosen to represent a higher mammalian species. In all control cells, the RIPlacZ gene failed to display lacZ gene expression, whereas the RSVlacZ gene resulted in expression of the ␤-galactosidase protein in the same cells. In NIT-1 cells, the RIPlacZ gene consistently expressed ␤-galactosidase protein.
These results show that insulinoma cells can be targeted in vitro using RIP.
Dose-response curves with ganciclovir for untransfected NIT-1 and F9 cells were performed before the cytoxicity studies with genetic constructs. Ganciclovir was found to be Vol. 233 • No. 5
Beta Cell-Specific Gene Therapy toxic to untransfected NIT-1 cells at much lower doses than reported in the literature for other cell types. [13] [14] [15] [16] [17] The ganciclovir toxicity dose-response curve for F9 cells resembled other cell lines. Therefore, it was determined that 0.20 g/mL was the maximum dose of ganciclovir used to treat NIT-1 cells in culture. We suspect that this observation is related to the fastidious nature of NIT-1 cells in culture because it is not reproducible in vivo.
The maximum transfection efficiency for NIT-1 cells in vitro was 10% in this experiment. This was shown using both the RIPlacZ gene and the RSVlacZ gene. Despite this transfection efficiency, a 26% decrease in cell survival was observed in NIT-1 cells transfected with the RIPtk gene. We believe this can be accounted for by the bystander effect resulting from the transfer of viral tk proteins into cells through gap junctions. 21 This allows for cells that were not originally transfected with a viral tk gene to become susceptible to the cytoxicity of ganciclovir, thereby increasing the number of cells being killed.
The data suggest that a beta cell tumor line, NIT-1, can be targeted in vitro for genetic manipulation using RIP. The RIPtk genetic construct resulted in NIT-1-specific cytoxicity. F9 cells showed no decrease in cell survival with the RIPtk gene, suggesting that there was no transcription of the tk gene with RIP in F9 cells. RIP can achieve beta cellspecific cytoxicity with the tissue-specific activation of tk.
To explain RIP activation in NIT-1 cells, RT-PCR was performed on whole RNA isolated from NIT-1 cells, looking for the presence of known RIP transcription factors BETA2 and PDX-1. The 502 base pairs used in this experiment contain six E box binding sites for BETA2 and three PDX-1 sites. Both transcription factors were found in NIT-1 cells. This may explain the activation of RIP in NIT-1 cells.
To examine further whether BETA2 and PDX-1 are responsible for RIP activation in this insulinoma cell line, NIT-1 cell nuclear extract was obtained and assayed to determine whether any nuclear proteins bound to either the BETA2 or PDX-1 binding sites would be found on RIP. Once binding was established, an antibody specific for BETA2 and PDX-1 was added to determine whether the BETA2 and PDX-1 proteins were the nuclear proteins binding to RIP. The data suggest that the transcription factors BETA2 and PDX-1 are both present in NIT-1 cell and that these transcriptional proteins bind to RIP.
The development of an insulinoma mouse model has allowed the examination of RIP-driven promoter-specific gene therapy in vivo. Stephens et al 22 have previously shown that NIT-1 cell tumors will develop if injected subcutaneously into NOD/SCID (nonobese diabetic) mice. However, the tumor model presented in this paper represents a novel mouse insulinoma model. Intraperitoneal seeding of tumor cells in nondiabetic mice, leading to hypoglycemic death, better mimics the natural disease than subcutaneous injection of the tumor cells.
The rat insulin promoter was successful in targeting NIT-1 tumor cells in vivo. The RIPtk gene in concert with ganciclovir was able to prevent hypoglycemia and prevent tumor growth in NIT-1-injected mice. The mouse that died of hypoglycemia had a technical problem with the administration of the RIPtk gene; it was injected into the bladder. The other mice have been followed up for 8 months with increases in their basal blood glucose levels, suggesting that the RIPtk did not affect the native islets; however, further studies are needed.
Currently, surgical resection is the only proven therapy for insulinomas. There is no medical therapy for recurrent or metastatic insulinomas. Our data suggest that hypoglycemia can be prevented in mice that have insulinomas using promoter-specific suicide gene therapy. The mechanism of RIP-specific activation is mediated by the insulinoma-specific expression of the transcription factors PDX-1 and BETA2. Beta Cell-Specific Gene Therapy Discussion DR. B. MARK EVERS (Galveston, Texas): I would like to compliment Drs. Tirone and Brunicardi for continuing to evaluate potentially novel therapies for the treatment of GI endocrine tumors. In this study, Dr. Brunicardi and his group have used the insulin promoter to direct the expression of the suicide gene thymidine kinase to insulinoma cells. They demonstrate that this therapy can prevent hypoglycemic-induced death noted in mice injected with the NIT-1 insulinoma cells. I have three questions for Dr. Tirone regarding these studies.
My first question concerns the method of vector delivery; that is, using liposomes injected intraperitoneally. I would like the authors to comment on the transfection efficiency of such a delivery system as opposed to intravenous injection of the liposome mixture. Also, would they comment on the length of time in which the gene is expressed, since with many in vivo transfections there is a rapid decline in the expression of the gene of interest. If the efficiency of entry into the cells by the vectors is low and the expression rapidly declines, then clinical applicability will be greatly hindered.
My second question has to do with the fact that in your paper you state that no identifiable tumors were located in the mice that died of hypoglycemia after injection of the NIT-1 cells, with the exception of one mouse. I was wondering what the mechanism of action is for the hypoglycemia if no identifiable tumors are present.
Finally, the most crucial question has to do with potential untoward effects in the normal pancreas with this type of treatment. If you are using the insulin promoter to drive expression into insulin-producing insulinoma cells, then one would think that this process is also occurring in normal beta cells of the pancreas. Have you looked at the normal pancreas to see if there is destruction of the normal beta cells? The other drawback to this potential therapy is the high bystander effect noted by a number of investigators using thymidine kinase-that is, normal acinar cells of the pancreas could be destroyed in a nonspecific fashion after activation of the thymidine kinase gene. Therefore, one could conceivably produce a situation where the treatment is worse than the disease if there is now destruction of not only normal beta cells but also normal surrounding acinar cells of the pancreas.
I thank the authors again for bringing this exciting and novel work to the Southern Surgical Association. With considerable refinement, these techniques may hold considerable future promise for novel treatment strategies. I appreciate receiving a copy of the manuscript and look forward to your further work in this area. Thank you.
DR. CHARLES YEO (Baltimore, Maryland): I, too, rise to congratulate Drs. Tirone and Brunicardi and their colleagues for a group of experiments that are not only potentially applicable to patients with metastatic insulinoma, which I suspect is not a major component of the patient visits seen by the surgeons in this audience, but whose overall concept and strategy holds future promise for the treatment of many diseases where overexpression of one gene and overabundance of one protein causes human disease. Dr. Evers had the opportunity to go first, and I'd like to thank Mark for asking several of my questions, but I do have two additional questions for the authors.
The in vivo beta cell adenoma model that you have created here appears to be a relatively rapidly lethal model with notable measurable hypoglycemia only days before death. Do you have insulin data to corroborate and prove that this is in fact insulin-induced hypoglycemic death and not some other form of an insulin-like protein?
Second question: The strategy linking a gene promoter to thymidine kinase and ganciclovir therapy appears potentially efficacious for not only hormone oversecretion syndromes such as insulinoma, gastrinoma, etc., but also for neoplasms driven by gene amplification or other oncogenes. What do you see as the further applications of this particular suicide gene strategy?
Again, my congratulations for a wonderful paper and a wonderful presentation.
DR. T. A. TIRONE (Houston, Texas): I would like to thank Dr. Evers and Dr. Yeo for their very good and pointed questions. To address Dr. Evers' first question regarding liposome transfection efficiency: We have shown in vitro and in vivo model that our transfection efficiency is roughly 8% to 10%. However, we do show a much larger kill efficiency, and this can be attributed, as he has stated, to the bystander effect. However, the advantages of using our liposomes allows us to redose if necessary.
Going to the kinds of gene expression, while Dr. Brunicardi noted that we, in our experiment, looked at our referred gene after 3 days, it has been shown (Dr. Templeton has shown in her work using liposomes) that gene expression can last up to 15 days. However, we are currently doing an experiment comparing both IP to IV injection of our genes and doing the timing of how long gene expression will last.
You asked another good question about tumor identification. Unfortunately, our models have to be housed in a SCID mouse barrier due to their immunodeficiency, and the mice, unfortunately, die in the middle of the night and are put into the freezer area. This does not allow us to perform necropsies on the deceased mice, and therefore a great deal of tissue is wasted. But as we have shown with our mice that we sacrificed after 3 days, did not wait for them to die of hypoglycemia, we were able to demonstrate tumors in these mice.
And, lastly, looking at the effect on beta cells in the surrounding pancreas, this is again a very good question. We have looked at the effect of RIPtk gene in the normal mouse. We have given them the RIPtk gene followed by 7 days of ganciclovir and after 4 months we have not shown any differences in blood glucose values. However, we do need to investigate the actual pancreas, looking at H&E stainings in both, looking at insulin and glucagon staining of the beta cells to see if there is surrounding damage.
Dr. Yeo's questions regarding insulin levels: again, that is another good question. The way our model is designed, you are looking at death as an end point, and we did not want to, for our first set of experiments, affect the outcome by bleeding the mice looking for the insulin levels. In order to obtain the insulin, which you have to do either rectal bleeds or very large tail bleeds, the amount of blood that is taken could affect the life span of the mice, so we did not want to do that for this experiment. However, we are looking into insulin levels.
And, lastly, the idea of our experiment in this rather rare cancer is that we are trying to combine molecular biology with surgery on the order of designing tumor-specific therapies for the treatment of disease, both adjuvant to surgery and in place of surgery for some other disease. We have been able to show with other cancers, especially human pancreatic ductal adenocarcinoma, that if you can identify the transcription factors to activate a promoter and make that promoter-specific therapy, that you can affect disease and a wide range of tumors without affecting the host. Again, I would like to thank Dr. Yeo and Dr. Evers and the Society for giving me the opportunity to present and answer these questions.
